Strut Health Medical Leadership and Credentials: An Independent Review

What Is Strut Health and How Does Its Clinical Model Work?

Strut Health operates as a direct-to-consumer telehealth company that connects patients with licensed physicians through an asynchronous text-and-photo intake process. Patients complete a detailed questionnaire, attach photos where relevant, and a physician reviews the case and issues a prescription if appropriate. The platform does not conduct live video visits for most of its standard offerings.

The Asynchronous Model: What It Means Clinically

Asynchronous telehealth has genuine advantages for low-acuity, well-defined conditions. The FDA has recognized telehealth's role in expanding access to FDA-approved therapies, and the agency's guidance on prescription drug distribution makes clear that a valid prescriber-patient relationship can be established without a synchronous visit in most states. FDA prescribing guidance outlines the conditions under which these relationships are considered valid.

For finasteride, sildenafil, and tadalafil, three of the most commonly prescribed drugs on the Strut platform, the clinical decision tree is relatively straightforward. Guidelines from the American Urological Association confirm that oral PDE5 inhibitors like sildenafil and tadalafil are first-line therapy for erectile dysfunction in most men without contraindications. AUA ED guidelines support this categorization, though prescribing still requires a valid patient history.

The asynchronous model does carry risk. A physician reviewing a static questionnaire cannot perform a physical exam, cannot assess blood pressure in real time, and relies entirely on patient-reported information. For finasteride, the FDA label (FDA finasteride label) requires that prostate cancer be ruled out before initiation, which is difficult to confirm without a PSA test or physical exam. Strut's intake process requests self-reported history but does not require lab work for most hair-loss prescriptions.

State Licensing and the IMLC

Strut physicians must hold active licenses in each state where they prescribe. The Interstate Medical Licensure Compact (IMLC) has expanded the ability of physicians to hold multistate licenses efficiently. The Federation of State Medical Boards maintains public records of physician discipline, and patients can verify any Strut-assigned prescriber through their state medical board's public lookup tool.

Strut has not published a full roster of its prescribing physicians with license numbers. This is not unique to Strut, most asynchronous telehealth platforms treat their physician network as a proprietary operational asset, but it does limit independent credential verification without a case-specific inquiry.

Is Strut Health Legitimate? Regulatory and Certification Status

Strut Health is a legitimate telehealth operation in the sense that it employs licensed physicians, uses a LegitScript-certified pharmacy network, and operates within the legal framework for telehealth prescribing in the states it serves. Legitimacy has layers, though, and patients should examine each one.

LegitScript Certification

LegitScript is the primary third-party certification body for online pharmacies and telehealth platforms. LegitScript certification means the platform has been reviewed against criteria including physician licensing, prescription requirements, and compliance with U.S. Pharmacy law. Strut Health holds LegitScript certification, which is a meaningful minimum-bar indicator of legitimacy. LegitScript's certification standards require ongoing compliance monitoring, not just a one-time review.

FDA Drug Approval Status for Core Offerings

The FDA has approved finasteride 1 mg (brand name Propecia) for male androgenetic alopecia and finasteride 5 mg (Proscar) for benign prostatic hyperplasia. The FDA approval record for finasteride confirms this. Minoxidil topical solution is FDA-approved for androgenetic alopecia. Sildenafil and tadalafil are FDA-approved for erectile dysfunction. These are not experimental drugs.

Where Strut moves into less regulated territory is with compounded medications and peptides. FDA-approved semaglutide (Ozempic, Wegovy) is available through compounding pharmacies during shortage periods, but the FDA has made clear that compounded semaglutide is not FDA-approved and carries different safety and efficacy assumptions. The FDA's statement on compounded semaglutide from 2024 explicitly notes that compounded versions have not been shown to be safe or effective to the same standard as the approved product.

BBB Standing and Consumer Complaints

As of early 2025, Strut Health is not accredited by the Better Business Bureau. The BBB profile (BBB Strut Health profile) reflects a moderate number of consumer complaints, with themes including billing disputes, shipping delays, and dissatisfaction with prescription denials after payment. Complaint resolution rates are mixed. None of the complaints on record allege clinical harm from a specific drug prescribed through the platform.

The absence of BBB accreditation does not mean the company is fraudulent. Many legitimate telehealth companies operate without BBB accreditation. The complaint pattern at Strut is broadly similar to that seen at comparable platforms, most issues are operational rather than clinical. Patients should read recent reviews on multiple platforms before committing to a subscription.

Medical Leadership at Strut Health: What Is Publicly Known?

Strut Health's medical leadership is not prominently featured on its public website. The platform does not prominently display a Chief Medical Officer, a medical advisory board, or individual physician profiles with license numbers on its consumer-facing pages. This stands in contrast to companies like Hims (which has published CMO commentary) or Teladoc Health (which maintains a named clinical leadership team).

Who Prescribes at Strut?

Strut employs or contracts with physicians who are licensed in the states they serve. The platform has referenced internal clinical protocols in its help documentation, suggesting some degree of standardized medical decision-making. The American Medical Association's Telehealth Policy recommends that telehealth platforms disclose prescriber credentials to patients on request, a standard Strut nominally meets, patients assigned to a physician can request credential information from customer support.

The lack of proactive credential disclosure is a transparency gap. Patients using Strut for a finasteride or semaglutide prescription may not know whether their prescriber is a dermatologist, a family medicine physician, or a general practitioner with no subspecialty training in the area being treated.

Clinical Protocols and Evidence Base

For its core hair-loss products, Strut's prescribing approach aligns with published clinical evidence. A 2-year randomized controlled trial published in the Journal of the American Academy of Dermatology showed that finasteride 1 mg/day produced a statistically significant increase in hair count vs. Placebo at 24 months (PubMed: finasteride hair loss RCT). Minoxidil 5% topical solution showed superior efficacy to 2% in a double-blind trial (PubMed: minoxidil 5% vs 2%). Strut's combination finasteride-minoxidil offerings are consistent with clinical practice guidelines from the American Academy of Dermatology, which support combination therapy for androgenetic alopecia. AAD hair loss guidelines endorse this approach.

For ED, the evidence base is equally solid. A meta-analysis of 82 randomized trials (N=19,616) published in the European Urology journal found that PDE5 inhibitors produced significantly greater improvement in International Index of Erectile Function scores than placebo, with tadalafil showing a favorable duration profile for daily use (PubMed: PDE5 inhibitor meta-analysis). Strut's sildenafil and tadalafil offerings are at doses consistent with FDA labeling.

Peptide Offerings: A Higher-Risk Category

Strut offers peptides including sermorelin and other growth-hormone secretagogues, as well as compounded semaglutide in some markets. This segment carries greater regulatory and safety complexity than the hair and ED categories.

Sermorelin and the FDA Regulatory Status

Sermorelin was previously FDA-approved (as Geref Diagnostic) but that approval was withdrawn in 2008. FDA's drug database shows no currently approved sermorelin product. Compounded sermorelin is legal under 503A pharmacy rules when prescribed for an individual patient with a specific clinical need, but it is not FDA-approved and has not been evaluated in large-scale phase III trials for the anti-aging or body-composition indications most patients seek.

The FDA has flagged certain peptides as "difficult to compound" substances. BPC-157 and TB-500, sometimes offered at adjacent telehealth platforms, appear on the FDA's list of substances that may not be compounded. Strut's current catalog should be verified against FDA's current compounding guidance before purchase, as offerings change.

Compounded Semaglutide: The Current Situation

During the FDA-declared shortage of semaglutide (Ozempic and Wegovy), 503A and 503B compounding pharmacies were legally permitted to produce compounded semaglutide. The FDA removed semaglutide from the shortage list in early 2024 for Wegovy and later for Ozempic, which means compounded semaglutide is no longer automatically permitted under the shortage exemption. The FDA's compounding FAQ is the authoritative source on current status, and patients considering compounded semaglutide through any platform, including Strut, should verify that the compounding pharmacy holds current 503A or 503B registration.

Clinical evidence for semaglutide in weight management is strong for the branded product. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks vs. 2.4% with placebo (P<0.001). STEP-1 full text in NEJM is the primary reference. Whether compounded semaglutide delivers equivalent pharmacokinetics is unknown, as no published phase III data exists for compounded versions.

How Strut Compares to Regulatory Benchmarks for Telehealth Quality

Several federal and professional guidelines define what responsible telehealth prescribing looks like. Measuring Strut against these benchmarks gives a clearer picture than consumer reviews alone.

Ryan Haight Act Compliance

The Ryan Haight Online Pharmacy Consumer Protection Act requires that a practitioner conduct at least one in-person medical evaluation before prescribing a controlled substance via the internet, with limited DEA-registered exceptions. Finasteride and most ED drugs are not controlled substances, so this law does not restrict Strut's primary offerings. However, it is relevant if Strut or its partner pharmacies ever dispense scheduled compounds. Patients can verify compliance expectations at DEA's telemedicine guidance page.

FSMB Telemedicine Policy Alignment

The Federation of State Medical Boards published model policy guidelines for the appropriate use of telemedicine in 2014, updated in subsequent years. Key standards include establishing a valid patient-physician relationship, maintaining patient records, and ensuring continuity of care. FSMB telemedicine policy states: "The standard of care is not altered by the fact that the patient is being treated via telemedicine." Strut's asynchronous model can meet this standard when physicians conduct thorough chart reviews, but the platform's lack of transparent audit mechanisms makes independent verification difficult.

Pharmacy Partner Quality

The quality of the compounding pharmacy matters as much as the physician's credentials. 503A pharmacies are regulated by state boards of pharmacy; 503B outsourcing facilities are regulated by the FDA. FDA's list of registered 503B outsourcing facilities is publicly searchable. Patients should ask Strut which specific compounding pharmacy will fulfill their prescription and verify that pharmacy's registration status before submitting payment.

Strut Health Complaints: Patterns and Clinical Significance

Consumer complaints about Strut Health fall into three broad categories when analyzed across the BBB, Trustpilot, and Reddit communities: billing and subscription disputes, fulfillment delays, and prescription denials. None of the publicly documented complaints reference a serious adverse drug event or a prescribing error that caused documented harm. This is consistent with the platform's focus on low-risk, widely-prescribed medications.

Billing Disputes

Subscription billing complaints are the most common category. Patients report difficulty canceling auto-renew subscriptions and unexpected charges after initial consultations. These are operational problems, not clinical ones, but they reflect a customer-service structure that can frustrate patients managing chronic medication use.

Prescription Denials

Some patients report paying the consultation fee and receiving a denial without a refund. Strut's policy, as described in its terms of service, does not guarantee a prescription. This is legally appropriate, physicians cannot be compelled to prescribe, but the lack of a refund-on-denial policy creates a financial disincentive to honest disclosure in the intake questionnaire, which could have clinical downstream effects.

The following framework can help patients evaluate any asynchronous telehealth platform before purchase:

1. Confirm the platform's LegitScript certification at legitscript.com.
2. Verify the prescribing physician's license via the FSMB physician lookup or your state medical board.
3. Confirm the dispensing pharmacy's registration at FDA's outsourcing facility list or your state board of pharmacy.
4. Check whether the drug being prescribed is FDA-approved for your indication at FDA DailyMed.
5. Review the platform's refund and cancellation policy in writing before submitting payment.

What Patients Should Ask Before Using Strut Health

A responsible approach to any telehealth platform starts with specific questions rather than general impressions. For Strut specifically, the following questions are worth answering before initiating treatment.

For Hair Loss Prescriptions

Finasteride carries a class label warning about sexual side effects, including post-finasteride syndrome (PFS), a condition reported by some patients involving persistent sexual, neurological, and psychological symptoms after discontinuation. The FDA updated the finasteride label in 2012 to include this information. FDA finasteride label update is the authoritative reference. Patients should confirm that their Strut physician has documented this discussion in their chart.

For ED Prescriptions

Sildenafil and tadalafil are contraindicated with nitrate medications due to the risk of severe hypotension. The FDA labeling for sildenafil (FDA sildenafil label) makes this contraindication explicit. Patients should confirm that Strut's intake questionnaire specifically screens for nitrate use and that their chart reflects a physician review of this contraindication.

For Peptide or Compounded Semaglutide Prescriptions

Ask the specific name and 503A or 503B registration number of the compounding pharmacy. Verify the registration at FDA's compounding registration database. Confirm in writing that the compound's ingredients are not on the FDA's list of substances that may not be compounded. The FDA bulk drug substances list is the reference document.